Tag Archives: public policy

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

Todd

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Video: Emerging Company CEOs Praise JOBS Act

medical_research

Passed in 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. In this short video, leading BIO Board Members and biotech company CEOs share the reasons why they feel the JOBS Act is critically important for today’s biotech industry. The JOBS Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

San Francisco Business Times: Two JOBS Acts are better than one

scientist-eyedropper

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Strongly Supports R&D Tax Credit Legislation

cells115x76

The House Ways and Means Committee posted the following message on its home page showing the support of several organizations, including BIO, for the American Research & Competitiveness Act (H.R. 4438): “Today, the National Association of Manufacturers, Chamber of Commerce, R&D Credit Coalition, and Biotechnology Industry Organization – representing thousands of small and large U.S. businesses – issued their support for H.R. 4438, a bipartisan, permanent extension of the research and development (R&D) tax credit. In their call for a permanent R&D Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Corporate-Sponsored University Research Valuable for Further Innovation

SBIR Reauthorization Moves Forward

New research published in Nature, Technology Transfer: Industry-funded academic inventions boost innovation, provides data undermining “assumptions that corporate-funded academic research is less accessible and useful to others.” After reviewing empirical evidence covering 20 years of inventions in the University of California system the authors find that: “Corporate-sponsored research is surprisingly valuable for further innovation. Data collected over 20 years at nine campuses and three national laboratories administered by the University of California show that corporate-sponsored Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,